Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 6:13:879516.
doi: 10.3389/fimmu.2022.879516. eCollection 2022.

Cardiovascular Involvement in Sjögren's Syndrome

Fabiola Atzeni  1 , Francesco Gozza  1 , Giacomo Cafaro  2 , Carlo Perricone  2 , Elena Bartoloni  2
Affiliations
Review

Cardiovascular Involvement in Sjögren's Syndrome

Fabiola Atzeni et al. Front Immunol. .

Abstract

Sjögren Syndrome (SS) seems to be associated with a greater "overall risk" of cardiovascular (CV) and cerebrovascular events. Although not conventionally considered a feature of the disease, CV events represent a major burden in SS patients. CV risk is the consequence of a complex combination of multiple factors, including traditional risk factors and disease-related mechanisms. A complex relationships between disease-related features, endothelial dysfunction and traditional risk factor has been suggested. Several drugs are available for treating the systemic manifestations of SS, however they have shown positive effects on different outcomes of the disease, but until today the data on the role of these drugs on CV events are scarse. Given these data, the aim of this review was to evaluate the risk of CV risk in primary SS and the effect of the drugs on this manifestation.

Keywords: Sjögren’s syndrome; cardiovascular risk; drugs; heart; risk factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The figure shows some of the main pathogenic mechanisms of subclinical atherosclerosis in Sjogren’s Syndrome.
See this image and copyright information in PMC

References

    1. Mariette X, Criswell LA. Primary Sjögren’s Syndrome. N Engl J Med (2018) 379(10):931–39. doi: 10.1056/NEJMcp1702514 - DOI - PubMed
    1. Mavragani CP, Fragoulis GE, Rontogianni D, Kanariou M, Moutsopoulos HM. Elevated IgG4 Serum Levels Among Primary Sjögren’s Syndrome Patients: Do They Unmask Underlying IgG4-Related Disease? Arthritis Care Res (Hoboken) (2014) 66(15):773–7. doi: 10.1503/cmaj.12203710.1002/acr.22216 - DOI - PubMed
    1. Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al. . EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI): Development of a Consensus Patient Index for Primary Sjögren’s Syndrome. Ann Rheumatol Dis (2011) 70(6):968–72. doi: 10.1136/ard.2010.143743 - DOI - PubMed
    1. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. . EULAR Sjogren’s Syndrome Disease Activity Index: Development of a Consensus Systemic Disease Activity Index for Primary Sjogren’s Syndrome. Ann Rheumatol Dis (2010) 69(6):1103–9. doi: 10.1136/ard.2009.110619 - DOI - PMC - PubMed
    1. Gyöngyösi M, Pokorny G, Jambrik Z, Kovàcs A, Makula E, Csanàdy M. Cardiac Manifestations in Primary Sjögren’s Syndrome. Ann Rheum Dis (1996) 55:450–4. doi: 10.1136/ard.55.7.450 - DOI - PMC - PubMed